semaglutide prediabetes weight loss trial progression to diabetes (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial or reach Semaglutide 2.4 mg clinical outcomes

The doctor report feature lets you export a summary of your logged data to share with your prescriber, which can make conversations about next steps including whether a change in approach is worth discussing more grounded and productive

Setting Realistic Expectations Patients can consider multiple strategies when they hit the maximum dose of GLP-1, but arent seeing the desired weight loss

If you experience these, follow your diabetes team's advice on managing low blood sugar, typically involving consuming fast-acting carbohydrates

Gut health connection

Yet, securing prior authorization (PA) approval from insurers remains a critical barrier

Meal-stimulated plasma GLP-1 levels in response to a liquid meal test (187.5 ml, 450 kcal, 17.5 g fat, 54.0 g carbohydrate, 19.1 g protein, Abbott Ensure) were measured at baseline, fasted (0 min = T0) and 30 min after starting the liquid meal (T30)